바이오마커 기반 면역측정법 시장 규모, 점유율, 동향 분석 보고서 : 샘플별, 제품별, 바이오마커별, 질환별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Biomarker-based Immunoassays Market Size, Share & Trends Analysis Report By Sample (Blood, Saliva, Tissue, Urine) By Product (Reagents & Kits, Consumables), By Biomarker, By Diseases, By End-use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,473,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,897,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,745,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

바이오마커 기반 면역측정법 시장 요약

세계 바이오마커 기반 면역측정법 시장 규모는 2024년 51억 5,000만 달러로 평가되며 2025년부터 2033년까지 CAGR 5.4%로 성장하여 2033년에는 83억 3,000만 달러에 달할 것으로 예상됩니다.

시장 성장의 원동력은 암, 심혈관질환, 신경질환 등 만성질환의 전 세계적인 부담 증가이며, 이러한 질환은 정밀하고 빠른 진단 도구가 필요합니다.

맞춤형 의료에 대한 수요가 증가함에 따라 임상의와 제약회사는 바이오마커 유도 전략을 채택하고 있으며, 면역 측정은 질병 검출과 치료 모니터링 모두에서 중심적인 역할을 하고 있습니다. 동반진단 약물에 대한 의존도가 높아지고, 바이오마커 기반 질병 개발에 대한 규제 당국의 지원으로 면역 측정법은 현대 의학에 필수적인 기술로 확고한 입지를 다지고 있습니다. 또한, 중개 연구 및 임상 진단에 대한 공공 및 민간 투자로 인해 병원, 연구소, 학술 기관에서의 도입이 가속화되고 있습니다.

다중화 플랫폼, 하이스루풋 분석기, 차세대 면역측정법 시스템을 통해 민감도와 특이성을 향상시킨 여러 바이오마커의 동시 검출이 가능해지면서 기술의 발전은 시장의 범위를 재구성하고 있습니다. 인공지능(AI)과 머신러닝(ML)을 바이오마커 기반 검사에 통합하여 데이터 해석을 개선하고, 액체 생검 기반 면역 측정법은 종양학 및 신경학 진단을 위한 최소침습적 옵션을 제공합니다. 또한, 정밀의학에서 점점 더 가치가 높아지고 있는 예측 및 예후 바이오마커에 특화된 시약 및 키트 개발도 진행하고 있습니다. 이러한 기술 혁신은 진단의 정확도를 높일 뿐만 아니라 납기를 단축하고, 바이오마커 면역 측정을 보다 친숙하고 임상적인 것으로 만듭니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 세계의 바이오마커 기반 면역측정법 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/보조적인 시장 전망.
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 세계의 바이오마커 기반 면역측정법 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 세계의 바이오마커 기반 면역측정법 시장 : 샘플 추정·동향 분석

• 부문 대시보드
• 세계의 바이오마커 기반 면역측정법 시장 샘플 변동 분석
• 세계의 바이오마커 기반 면역측정법 시장 규모와 동향 분석(샘플별, 2018-2030년)
• 혈액
• 조직
• 타액
• 소변

제5장 세계의 바이오마커 기반 면역측정법 시장 : 제품 추정·동향 분석

• 부문 대시보드
• 세계의 바이오마커 기반 면역측정법 시장 제품 변동 분석
• 세계의 바이오마커 기반 면역측정법 시장 규모와 동향 분석(제품별, 2021-2033년)
• 소모품
• 기기/분석기
• 시약과 키트
• 서비스

제6장 세계의 바이오마커 기반 면역측정법 시장 : 바이오마커 추정·동향 분석

• 부문 대시보드
• 세계의 바이오마커 기반 면역측정법 시장 바이오마커 변동 분석
• 세계의 바이오마커 기반 면역측정법 시장 규모와 동향 분석(바이오마커별, 2021-2033년)
• 안전성과 독성 바이오마커
• 유효성과 약력학적 바이오마커
• 예측 및 예후 바이오마커
• 대체/탐색적 바이오마커

제7장 세계의 바이오마커 기반 면역측정법 시장 : 질환 추정·동향 분석

• 부문 대시보드
• 세계의 바이오마커 기반 면역측정법 시장 질환 변동 분석
  • 세계의 바이오마커 기반 면역측정 시장 규모와 동향 분석(질환별, 2021-2033년)
• 암
• 심혈관질환
• 신경질환
• 면역질환
• 기타

제8장 세계의 바이오마커 기반 면역측정법 시장 : 최종 용도 추정·동향 분석

• 부문 대시보드
• 세계의 바이오마커 기반 면역측정 시장 최종 용도 변동 분석
  • 세계의 바이오마커 기반 면역측정법 시장 규모와 동향 분석(최종 용도별, 2021-2033년)
• 병원과 진료소
• 진단 검사실
• 연구·학술기관
• 기타

제9장 바이오마커 기반 면역측정법 시장 : 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2021-2033년 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제10장 경쟁 구도

• 기업/경쟁 분류
• 전략 매핑
• 기업 시장 점유율 분석, 2024년
• 주요 인증 프로바이더/스킴 소유자 리스트
• 기업 개요/상장 기업
  • F. Hoffmann-La Roche AG
  • Abbott
  • Thermo Fisher Scientific Inc
  • Eurofins Scientific
  • QIAGEN
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG
  • Merck KGaA
  • PerkinElmer Inc.
  • Agilent Technologies, Inc.

KSM

영문 목차

영문목차

Biomarker-based Immunoassays Market Summary

The global biomarker-based immunoassays market size was valued at USD 5.15 billion in 2024 and is expected to reach USD 8.33 billion by 2033, growing at a CAGR of 5.4% from 2025 to 2033. The market growth is fueled by the rising global burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which require precise and early diagnostic tools.

Increasing demand for personalized medicine has driven clinicians and pharmaceutical companies to adopt biomarker-guided strategies, where immunoassays play a central role in both disease detection and therapeutic monitoring. The increasing reliance on companion diagnostics, along with regulatory support for biomarker-driven disease development, has solidified immunoassays as an essential technology in modern healthcare. Additionally, public and private investments in translational research and clinical diagnostics have sped up adoption across hospitals, laboratories, and academic institutions.

Technological advancements are also reshaping the scope of the market, with multiplexing platforms, high-throughput analyzers, and next-generation immunoassay systems enabling the simultaneous detection of multiple biomarkers with enhanced sensitivity and specificity. The integration of artificial intelligence (AI) and machine learning (ML) into biomarker-based testing improves data interpretation, while liquid biopsy-based immunoassays offer less invasive options for oncology and neurology diagnostics. Companies are also developing reagents and kits tailored for predictive and prognostic biomarkers, which are increasingly valuable in precision medicine. These innovations not only enhance diagnostic accuracy but also reduce turnaround times, making biomarker immunoassays more accessible and clinically relevant.

Global Biomarker-based Immunoassays Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the biomarker-based immunoassays market on the basis sample, product, biomarkers, diseases, end-use, and region:

• Sample Outlook (Revenue, USD Million, 2021 - 2033)
• Blood
• Tissue
• Urine
• Saliva
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Consumables
• Instruments/ Analyzers
• Reagent & Kits
• Services
• Biomarker Outlook (Revenue, USD Million, 2021 - 2033)
• Safety & toxicity biomarkers
• Efficacy & Pharmacodynamic Biomarkers
• Predictive & Prognostic Biomarkers
• Surrogate/Exploratory Biomarkers
• Diseases Outlook (Revenue, USD Million, 2021 - 2033)
• Cancer
• Cardiovascular Diseases
• Neurological Diseases
• Immunological Diseases
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Sample Segment
  • 1.2.2. Product Segment
  • 1.2.3. Biomarker Segment
  • 1.2.4. Diseases Segment
  • 1.2.5. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Biomarkerl
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global Biomarker-Based Immunoassays Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising demand for precision medicine and personalized therapies
    • 3.2.1.2. Increasing prevalence of chronic and infectious diseases
    • 3.2.1.3. Technological advancements in immunoassay platforms
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of advanced biomarker assays and platforms
• 3.3. Global Biomarker-Based Immunoassays Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Global Biomarker-Based Immunoassays Market: Sample Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Biomarker-Based Immunoassays Market Sample Movement Analysis
• 4.3. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by sample, 2018 to 2030 (USD Million)
• 4.4. Blood
  • 4.4.1. Blood market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Tissue
  • 4.5.1. Tissue market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Saliva
  • 4.6.1. Saliva market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Urine
  • 4.7.1. Urine market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Biomarker-Based Immunoassays Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Biomarker-Based Immunoassays Market Product Movement Analysis
• 5.3. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
• 5.4. Consumables
  • 5.4.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Instruments/Analyzers
  • 5.5.1. Instruments/Analyzers market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Reagent & Kits
  • 5.6.1. Reagent & kits market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Services
  • 5.7.1. Services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Biomarker-Based Immunoassays Market: Biomarker Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Biomarker-Based Immunoassays Market Biomarker Movement Analysis
• 6.3. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by biomarkers, 2021 to 2033 (USD Million)
• 6.4. Safety & toxicity biomarkers
  • 6.4.1. Safety & toxicity biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Efficacy & Pharmacodynamic Biomarkers
  • 6.5.1. Efficacy & Pharmacodynamic Biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Predictive & Prognostic Biomarkers
  • 6.6.1. Predictive & prognostic biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Surrogate/Exploratory Biomarkers
  • 6.7.1. Surrogate/exploratory biomarkers market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Global Biomarker-Based Immunoassays Market: Diseases Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Biomarker-Based Immunoassays Market Diseases Movement Analysis
  • 7.2.1. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by diseases, 2021 to 2033 (USD Million)
• 7.3. Cancer
  • 7.3.1. Cancer market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Cardiovascular Diseases
  • 7.4.1. Cardiovascular diseases market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Neurological Diseases
  • 7.5.1. Neurological diseases market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Immunological Diseases
  • 7.6.1. Immunological diseases testing market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Global Biomarker-Based Immunoassays Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Biomarker-Based Immunoassays Market End Use Movement Analysis
  • 8.2.1. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 8.3. Hospitals & Clinics
  • 8.3.1. Hospitals and clinics market estimates and forecasts 2021 to 2033 (USD Million)
• 8.4. Diagnostic Laboratories
  • 8.4.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Research & Academic Institutes
  • 8.5.1. Research & Academic Institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Others
  • 8.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Biomarker-Based Immunoassays Market: Regional Estimates & Trend Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework/ reimbursement structure
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework/ reimbursement structure
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework/ reimbursement structure
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework/ reimbursement structure
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/ reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/ reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework/ reimbursement structure
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework/ reimbursement structure
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework/ reimbursement structure
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework/ reimbursement structure
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework/ reimbursement structure
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/ reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework/ reimbursement structure
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework/ reimbursement structure
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Share Analysis, 2024
• 10.4. List of Key Certification Providers/Scheme Owners
• 10.5. Company Profiles/Listing
  • 10.5.1. F. Hoffmann-La Roche AG
    • 10.5.1.1. Company overview
    • 10.5.1.2. Financial performance
    • 10.5.1.3. Product benchmarking
    • 10.5.1.4. Strategic initiatives
  • 10.5.2. Abbott
    • 10.5.2.1. Company overview
    • 10.5.2.2. Financial performance
    • 10.5.2.3. Product benchmarking
    • 10.5.2.4. Strategic initiatives
  • 10.5.3. Thermo Fisher Scientific Inc
    • 10.5.3.1. Company overview
    • 10.5.3.2. Financial performance
    • 10.5.3.3. Product benchmarking
    • 10.5.3.4. Strategic initiatives
  • 10.5.4. Eurofins Scientific
    • 10.5.4.1. Company overview
    • 10.5.4.2. Financial performance
    • 10.5.4.3. Product benchmarking
    • 10.5.4.4. Strategic initiatives
  • 10.5.5. QIAGEN
    • 10.5.5.1. Company overview
    • 10.5.5.2. Financial performance
    • 10.5.5.3. Product benchmarking
    • 10.5.5.4. Strategic initiatives
  • 10.5.6. Bio-Rad Laboratories, Inc.
    • 10.5.6.1. Company overview
    • 10.5.6.2. Financial performance
    • 10.5.6.3. Product benchmarking
    • 10.5.6.4. Strategic initiatives
  • 10.5.7. Siemens Healthineers AG
    • 10.5.7.1. Company overview
    • 10.5.7.2. Financial performance
    • 10.5.7.3. Product benchmarking
    • 10.5.7.4. Strategic initiatives
  • 10.5.8. Merck KGaA
    • 10.5.8.1. Company overview
    • 10.5.8.2. Financial performance
    • 10.5.8.3. Product benchmarking
    • 10.5.8.4. Strategic initiatives
  • 10.5.9. PerkinElmer Inc.
    • 10.5.9.1. Company overview
    • 10.5.9.2. Financial performance
    • 10.5.9.3. Product benchmarking
    • 10.5.9.4. Strategic initiatives
  • 10.5.10. Agilent Technologies, Inc.
    • 10.5.10.1. Company overview
    • 10.5.10.2. Financial performance
    • 10.5.10.3. Product benchmarking
    • 10.5.10.4. Strategic initiatives

관련자료